---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-24-000057"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T15:58:21.582992+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA places clinical hold on vTv Therapeutics' cadisegliatin Phase 3 trial for type 1 diabetes

## Summary
- FDA clinical hold based on unresolved chromatographic signal in cadisegliatin ADME study.
- FDA requires a single in vitro study to characterize signal before program can resume.
- No patients had been dosed in CATT1 Phase 3 trial at time of hold; no prior safety issues.
- vTv is working with FDA to resolve hold and resume enrollment as quickly as possible.
- Cadisegliatin is an oral glucokinase activator; over 500 subjects dosed to date with favorable safety profile.

## SEC filing metadata
- accession: 0001641489-24-000057
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000057/0001641489-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000057/vtvt-20240726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-24-000057
- JSON: https://secwatch.observer/filing/0001641489-24-000057.json
- Plain text: https://secwatch.observer/filing/0001641489-24-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.